Home › Compare › CHDHF vs ABBV
CHDHF yields 1996.01% · ABBV yields 3.06%● Live data
📍 CHDHF pulled ahead of the other in Year 1
Combined, CHDHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CHDHF + ABBV for your $10,000?
Ev Dynamics (Holdings) Limited, an investment holding company, manufactures electric vehicles in the Philippines, Spain, Germany, and Mexico. It operates in three segments: Development of Electric Vehicles, Mining, and Metals and Minerals Trading. The company manufactures in electric buses, electric power and control systems, and other buses; and markets and sells vehicle components. It also owns the Glauberite Mine located in the Guangxi Zhuang Autonomous Region, the People's Republic of China. In addition, the company is involved in the manufacturing and trading of motor vehicles and batteries; trading of metals and minerals; mining and sale of mineral resources; and development and marketing of new energy technology and products. Further, it provides management and computer maintenance services; trades in computer hardware and software; and develops software. The company was formerly known as China Dynamics (Holdings) Limited and changed its name to Ev Dynamics (Holdings) Limited in July 2021. Ev Dynamics (Holdings) Limited was incorporated in 1996 and is headquartered in Wan Chai, Hong Kong.
Full CHDHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.